Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
The Permanente Journal|October 22, 2016
Development and Application of a Plant-Based Diet Scoring System for Japanese Patients with Inflammatory Bowel DiseaseMitsuro Chiba, Kunio Nakane, Yuko Takayama, et al.
The Permanente Journal|May 4, 2019
Relapse Prevention by Plant-Based Diet Incorporated into Induction Therapy for Ulcerative Colitis: A Single-Group TrialMitsuro Chiba, Kunio Nakane, Tsuyotoshi Tsuji, et al.
Clinical Biomechanics (Bristol, Avon)|April 16, 2019
Comparison of finite helical axes of normal and anatomically designed prosthetic kneesShoji Konda, Tetsuya Tomita, Takaharu Yamazaki, et al.
Translational Gastroenterology and Hepatology|August 4, 2025
Long-term durability of infliximab maintenance therapy incorporating plant-based diet in inflammatory bowel diseaseMitsuro Chiba, Tsuyotoshi Tsuji, Kunio Nakane, et al.
Internal Medicine (Tokyo, Japan)|June 5, 2024
Successful Treatment of Bilocular Walled-off Necrosis with Transmural Naso-cyst Continuous IrrigationMari Matsuyama, Hisanori Matsuzawa, Kazuya Kimura, et al.
The Permanente Journal|July 15, 2018
Relapse Prevention in Ulcerative Colitis by Plant-Based Diet Through Educational Hospitalization: A Single-Group TrialMitsuro Chiba, Kunio Nakane, Tsuyotoshi Tsuji, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 14, 2002
The expression of Fas and Fas ligand, and the effects of interferon in chronic liver diseases with hepatitis C virusKazuo Yoneyama, Takashi Goto, Kouichi Miura, et al.
Biochemical and Biophysical Research Communications|November 1, 2003
Epimorphin is involved in differentiation of rat hepatic stem-like cells through cell-cell contactKouichi Miura, Hirokazu Nagai, Yasuharu Ueno, et al.
Global Health & Medicine|September 19, 2022
No increased risk of hepatocellular carcinoma after eradication of hepatitis C virus by direct-acting antivirals, compared with interferon-based therapyMasaaki Korenaga, Kazumoto Murata, Namiki Izumi, et al.
The Lancet. Infectious Diseases|April 13, 2015
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trialMasashi Mizokami, Osamu Yokosuka, Tetsuo Takehara, et al.
Pageof 3